WILMINGTON, Del. / Apr 11, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024.
| The schedule for the press release and conference call/webcast is as follows: | |
| • Q1 2024 Press Release: | April 30, 2024 at 7:00 a.m. ET |
| • Q1 2024 Conference Call: | April 30, 2024 at 8:00 a.m. ET |
| • Domestic Dial-In Number: | 877-407-3042 |
| • International Dial-In Number: | 201-389-0864 |
| • Conference ID Number: | 13745743 |
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13745743.
The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
| Last Trade: | US$59.09 |
| Daily Change: | -0.13 -0.22 |
| Daily Volume: | 311,667 |
| Market Cap: | US$11.380B |
March 17, 2025 February 28, 2025 February 20, 2025 February 18, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
